Disease Progression Clinical Trial
Official title:
TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and compared to the initial (archival) tumor biopsy sample taken from the same patient. Annotated reports of results from clinical Next Generation Sequencing (NGS) gene panel tests of both tumor and blood are sent directly from the testing lab to the study physician for discussion with the patient during the study. Patients may participate in interventional treatment clinical trials at the same time as participating in the TRANSLATE study. Primary data will be publicly available after the study to support further research.
Background: Development of new cancer treatments requires better understanding of why tumors develop resistance to standard-of-care (SOC) therapies. However, post-progression tumor biopsies are not routinely collected, limiting the tissue available to characterize mechanisms of treatment resistance. The TRANSLATE clinical study is specifically designed to address these critical gaps. Trial design: TRANSLATE is a global, multicenter, translational study designed to collect and compare archival pre-treatment tumor tissue with paired de novo tumor and blood samples obtained following disease progression on SOC therapies, targeting therapeutically important areas of cancer biology. Eligible Tumor Type and Most Recent SOC Therapy: - Non-small-cell lung and Anti-PD-1/-L1 monotherapy - Non-small-cell lung and Anti-PD-1/-L1 + platinum - Clear cell renal cell carcinoma and Anti-PD-1/-L1 monotherapy - Clear cell renal cell carcinoma and Doublet anti-PD-1/-L1 + anti-CTLA-4 - Clear cell renal cell carcinoma and Pembrolizumab + axitinib - Clear cell renal cell carcinoma and Avelumab + axitinib - HR+ HER2- breast and Palbociclib + hormonal therapy - germline mutated BRCA breast and Olaparib or talazoparib monotherapy - Castration-resistant prostate and Enzalutamide - Castration-resistant prostate and Abiraterone + prednisone Eligibility criteria include adults with locally advanced or metastatic tumors; radiographic evidence of progressive disease during the most recent SOC regimen; sufficient archival tumor tissue; and a post-progression tumor lesion that is safely accessible for a new biopsy. The results from clinical NGS panel testing may help inform subsequent treatment plan or identification of relevant interventional clinical trials. Patients are enrolled after disease progression on SOC and before change in treatment and participate in 3 study visits within approximately 3 months. Next-generation sequencing results from analysis of tumor tissue and blood will be returned to the study physician and patient for review at a subsequent study visit within this timeframe. The primary endpoint is the change in frequency of gene alterations between pre-treatment and post-progression tumor biopsies. Secondary endpoints address prioritized scientific hypotheses specific to each target area of biology and indication. Primary data will be publicly available after the study to support further research. Sponsored by Pfizer Inc.; EudraCT: 2018-003612-45. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03474692 -
Virta Health Registry
|
||
Recruiting |
NCT05022147 -
Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease
|
Phase 1 | |
Not yet recruiting |
NCT04115787 -
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
|
||
Completed |
NCT01507415 -
Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?
|
N/A | |
Completed |
NCT04776837 -
Predicting Disease Progression and/or Recurrence in Cancer
|
||
Active, not recruiting |
NCT05085275 -
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01947127 -
Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
|
N/A | |
Completed |
NCT01923103 -
Natural Disease Progress of Dupuytren Disease
|
||
Active, not recruiting |
NCT02011932 -
Prospective Observational Study of Disease Progression in Chronic Hepatitis C
|
N/A | |
Not yet recruiting |
NCT05851209 -
Biomarkers and Mechanisms of Disease Progression and Outcome of Aortic Stenosis in Humans
|
||
Withdrawn |
NCT02134652 -
Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever
|
N/A | |
Recruiting |
NCT02753192 -
Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison
|
N/A | |
Terminated |
NCT00338091 -
Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency
|
N/A | |
Completed |
NCT04343456 -
Salvage Surgery for Patients With Metastatic GIST With Rego
|
||
Completed |
NCT03174912 -
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
|
Phase 4 | |
Completed |
NCT01425073 -
Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya
|
N/A | |
Terminated |
NCT02681809 -
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
|
Phase 2 | |
Completed |
NCT02499068 -
Madrid Project on the Management of Chronic Obstructive Pulmonary Disease With Home Telemonitoring
|
N/A | |
Completed |
NCT00567983 -
Topical Cyclosporine and Disease Progression
|
Phase 4 | |
Completed |
NCT05536206 -
Continuous and Wireless Vital Sign Monitoring in Patients at Home After Acute Medical Admission
|